Co-Diagnostics — Third Quarter 2026 Earnings Summary

Co-Diagnostics, Inc. reported third-quarter 2026 revenue of $0.3 million and a net loss of $6.3 million, or $1.01 per share. The company advanced two regulatory submissions under review, including a 510(k) for its Flu A/B & RSV test with the U.S. FDA and a tuberculosis test with India's CDSCO. Operating expenses decreased by 12% year-over-year to $6.2 million, driven by reduced personnel and stock-based compensation costs. Additionally, the company expanded its platform capabilities through new collaborations, international deployments, and the launch of cloud infrastructure in India.